Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: PROLIFE who wrote (516)	10/17/1998 3:16:00 PM
From: mammoth	Respond to of 1255

I don't think anyone can answer that question positively. However, I suspect that the market makers would want to buy all of the shares they could get at the lowest possible price. Thus, whenever anyone bought at the ask, they would not uptick. However, whenever anyone bought at the bid, they would downtick. This would effectively take the price lower, all the while picking up stop loss orders set near 1 along the way. This way, the market makers build up their own inventory of stock at a lower price in advance of the news. Then, after the news hits, they would be willing to move the price back up, since it makes their shares worth more. This is just my guess, but we will see on Monday whether it proves correct.

To: PROLIFE who wrote (516)	10/17/1998 3:17:00 PM
From: DavidCG	Respond to of 1255

CORX is engaged in HUMAN TESTING at the NATIONAL INSTITUTES of HEALTH! I was responding to a gentleman over on the NEOT board... because apparently people do not realize that CORX is in the middle of THREE HUMAN STUDIES with its compound. People are assuming (like I initially did) that CORX has only had success on rats, like ENMD has. (ENMD has had no human testing yet) That assumption is incorrect. These statements are from CORX's recent SEC filings: >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> AMPALEX (CX516) is currently being investigated in Phase I/IIa clinical trials at the National Institutes of Health (NIH) in Bethesda, in patients with Alzheimer's disease and patients with schizophrenia. An additional study in patients with schizophrenia is being conducted at the Erich Lindemann Mental Health Center in Boston. These trials follow three European studies that demonstrated that AMPALEX is safe and well tolerated on acute oral administration to healthy human volunteers. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> also: <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< Operating results for fiscal 1998 reflect ongoing clinical testing of AMPALEX(R) (CX516) in patients with Alzheimer's disease and those suffering from schizophrenia, said Vincent F. Simmon, Ph.D., President and Chief Executive Officer. ''As we reported earlier, we are pleased with the safety profile experienced to date in these double-blind trials. In addition, although the number of patients analyzed to date is too small to draw statistical conclusions, preliminary results suggest that CX516 improves performance on several tests of memory and cognition in patients with schizophrenia.'' <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< What is VERY interesting is that CORX just patented a compound which is 50 - 100 times stronger than what they are using in human testing currently! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Cortex has completed a preliminary human safety study with a second generation AMPAKINE, CX691. This compound was designed to have a longer half life in humans, and the preliminary study has confirmed that it does. Furthermore, in a number of animal behavior assay systems, CX691 appears to be 50 to 100 times more potent than CX516 and has an impressive margin of safety. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> What I like is that the National Institute of Health (US govt. operated) is testing CORX's drug...Talk about CREDIBILITY. -DavidCG